Annekatrin Müller

Annekatrin Müller

Auto-generated profile, based on publicly available information

Annekatrin Müller

Department and Policlinic of Neurology, Leipzig University Medicine, Leipzig, Germany

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 September 2023 in Annals of Intensive Care
Verified
Journal Article
Open access
PDF file
JHJulia Herzig-Nichtweiß
Julia Herzig-Nichtweiß
FSFarid Salih
Farid Salih
SBSascha Berning
Sascha Berning
MMMichael Malter
Michael Malter
JPJohann Pelz
Johann Pelz
BVBernd J. Vorderwülbecke
Bernd J. Vorderwülbecke
Acute symptomatic epileptic seizures are frequently seen in neurocritical care. To prevent subsequent unprovoked seizures, long-term treatments with antiseizure medications are often initiated although supporting evidence is lacking. This study aimed at prospectively assessing the risk of unprovoked seizure relapse with respect to the use of antiseizure medications. It was hypothesized that after a first acute symptomatic seizure of structural etiology, the cumulative 12-month risk of unprovoked seizure relapse is ≤ 25%. Inclusion criteria were age ≥ 18 and acute symptomatic first-ever epileptic seizure; patients with status epilepticus were excluded. Using telephone and mail interviews, participants were followed for 12 months after the acute symptomatic first seizure. Primary endpoint was the occurrence and timing of a first unprovoked seizure relapse. In addition, neuro-intensivists in Germany were interviewed about their antiseizure treatment strategies through an anonymous online survey. Eleven of 122 participants with structural etiology had an unprovoked seizure relapse, resulting in a cumulative 12-month risk of 10.7% (95%CI, 4.7%–16.7%). None of 19 participants with a non-structural etiology had a subsequent unprovoked seizure. Compared to structural etiology alone, combined infectious and structural etiology was independently associated with unprovoked seizure relapse (OR 11.1; 95%CI, 1.8–69.7). Median duration of antiseizure treatment was 3.4 months (IQR 0–9.3). Seven out of 11 participants had their unprovoked seizure relapse while taking antiseizure medication; longer treatment durations were not associated with decreased risk of unprovoked seizure relapse. Following the non-representative online survey, most neuro-intensivists consider 3 months or less of antiseizure medication to be adequate. Even in case of structural etiology, acute symptomatic seizures bear a low risk of subsequent unprovoked seizures. There is still no evidence favoring long-term treatments with antiseizure medications. Hence, individual constellations with an increased risk of unprovoked seizure relapse should be identified, such as central nervous system infections causing structural brain damage. However, in the absence of high-risk features, antiseizure medications should be discontinued early to avoid overtreatment.

23 September 2020 in Scientific Reports
Verified
Journal Article
Open access
PDF file
AMAnnekatrin Müller
Annekatrin Müller
JHJudith von Hofen-Hohloch
Judith von Hofen-Hohloch
MMMeinhard Mende
Meinhard Mende
DSDorothee Saur
Dorothee Saur
CFChristopher Fricke
Christopher Fricke
JCJoseph Classen
Joseph Classen
In this prospective cohort study we aimed to investigate the trajectory of the cognitive performance of patients after discharge from an intensive care unit (ICU). Special consideration was given to patients with suspected premorbid cognitive impairment who might be at risk for the development of dementia. Clinical characteristics were collected until discharge. The premorbid cognitive state was estimated by a structured interview with a close relative. Cognitive outcome was assessed using the Consortium to Establish a Registry of Alzheimer’s Disease (CERAD) Plus battery and the Stroop Color and Word Test at the time of discharge from ICU and 9 months later. The results of the study group were compared to an established healthy control group and to normative data. A total number of 108 patients were finally included. At the time of discharge, patients underperformed the healthy control group. In linear regression models, delirium during the ICU stay and the factor premorbid cognitive impairment were associated with poorer cognitive outcome (p = 0.047 and p = 0.001). After 9 months, in 6% of patients without evidence of premorbid cognitive impairment long-lasting deficits were found. In patients with suspected premorbid cognitive impairment, performance in tests of executive function failed to improve.

3 December 2020 in BMC Neurology
Verified
Journal Article
Open access
PDF file
AMAnnekatrin Müller
Annekatrin Müller
ASAnett Schmiedeknecht
Anett Schmiedeknecht
MMMeinhard Mende
Meinhard Mende
CACarolin Awissus
Carolin Awissus
FRFelix Rosenow
Felix Rosenow
JCJoseph Classen
Joseph Classen
Background: Status epilepticus (SE) is a common neurological emergency condition that especially affects the elderly and old population. Older people with SE frequently have non-convulsive SE (NCSE) and are also at special risk of suffering a poor outcome. The application of benzodiazepines fails to control SE in about one third of the cases. For benzodiazepine refractory SE (BRSE) in elderly, there is little evidence that would justify the choice of one of the commonly used antiepileptic drugs. The present study aims to generate evidence for the treatment of BRSE in this age group.Methods: We will conduct a prospective, randomized, double-blind comparative effectiveness study in more than twenty hospitals in Germany over a four-year period. Four hundred and seventy-seven elderly patients (≥ 65 years old) diagnosed with BRSE will be allocated by 1:1 randomization to receive either levetiracetam or valproate. All types of SE will be considered. For the diagnosis NCSE a verification by EEG is required. Levetiracetam or valproate will be administered in one single infusion. The primary endpoint is the stable cessation of ictal activity 15 min after the start of infusion persisting for the following 45 min of observation. EEG recording is maintained over the whole observation period, clinical examinations are conducted in predefined intervals. In case of treatment success patients and study staff remain blinded until 60 min after the start of the infusion. Adverse events will be recorded until the end of the study. EEG data will be reviewed by two external independent experts. To obtain data about the further treatment of SE, intrahospital complications and the functional outcome in the short term the study participants will be observed until the day of discharge or day 30 whichever is earliest.Discussion: ToSEE is the first study which shall deliver evidence for the SE-therapy in the elderly and old population in a controlled prospective comparator study. By design it also shall collect information about therapy regimes and outcome aspects of this disease.Trial registration: The trial has been registered at the German Clinical Trials Register on 3 July, 2020 (DRKS00022308, https://www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00022308).

9 September 2022 in The Cerebellum
Verified
Journal Article
Open access
PDF file
LBLaura Bindel
Laura Bindel
CMChristoph Mühlberg
Christoph Mühlberg
VPVictoria Pfeiffer
Victoria Pfeiffer
MNMatthias Nitschke
Matthias Nitschke
AMAnnekatrin Müller
Annekatrin Müller
ETElinor Tzvi-Minker
Elinor Tzvi-Minker
Essential tremor (ET) is a progressive movement disorder whose pathophysiology is not fully understood. Current evidence supports the view that the cerebellum is critically involved in the genesis of the tremor in ET. However, it is still unknown whether cerebellar dysfunction affects not only the control of current movements but also the prediction of future movements through dynamic adaptation toward a changed environment. Here, we tested the capacity of 28 patients with ET to adapt in a visuomotor adaptation task known to depend on intact cerebellar function. We found specific impairments in that task compared to age-matched healthy controls. Adaptation to the visual perturbation was disrupted in ET patients, while de-adaptation, the phase after abrupt removal of the perturbation, developed similarly to control subjects. Baseline tremor-independent motor performance was as well similar to healthy controls, indicating that adaptation deficits in ET patients were not rooted in an inability to perform goal-directed movements. There was no association between clinical severity scores of ET and early visuomotor adaptation abilities. These results provide further evidence that the cerebellum is dysfunctional in ET.

24 October 2022 in Neurological Research and Practice
Verified
Journal Article
Open access
PDF file
AMAnnekatrin Müller
Annekatrin Müller
JHJudith von Hofen-Hohloch
Judith von Hofen-Hohloch
CACarolin Awissus
Carolin Awissus
JPJens Przybilla
Jens Przybilla
AMAchmed Mrestani
Achmed Mrestani
JCJoseph Classen
Joseph Classen
Background: In the treatment of status epilepticus less is known about the influence of comorbidities on the safety profile of anticonvulsive drugs. Especially patients with diabetes mellitus may be predisposed to certain adverse events that have been related to therapy with valproic acid. In this single-center retrospective cohort study we examined if the complications of the intravenous treatment with valproic acid is different in patients with or without diabetes. Methods: Patients who were treated for status epilepticus with intravenous valproic acid between 2008 and 2020 were identified. Primary endpoint was the discontinuation of therapy with valproic acid due to adverse events. Relevant secondary endpoints were the functional status at the time of discharge from hospital in comparison to the premorbid state and the in-hospital mortality. Both groups (patients with or without diabetes) were compared by Mann–Whitney U-Test or Pearson´s Chi2 test. To identify therapy with valproic acid as a risk factor of in-hospital mortality, a binary regression model was used. Results: During the study period 408 patients and 482 episodes of status epilepticus were treated with intravenous valproic acid. Group comparisons did not reveal a significant difference in the rates of discontinuation of therapy. A difference was found in the rate of thrombocytopenia (p = 0.015), which occurred more often in patients with diabetes. In total, 36 hypoglycemic episodes could be identified, two occurred spontaneously under intravenous valproic acid. After correction for potential confounders, continuous therapy with valproic acid could not be confirmed as an independent risk factor for in-hospital mortality (p = 0.079). In patients with diabetes, the proportion of patients with a good functional state, indicated by the modified Rankin Scale, was significantly lower in both times (premorbid: 55% vs. 69%, p = 0.008; at discharge: 22% vs. 36%, p = 0.004). Conclusions: Tolerability of the treatment with valproic acid was similar in patients with or without diabetes. Diabetes as a relevant comorbidity can signal a potentially increased risk of a poor outcome after status epilepticus. Trial registration: The study was registered at the German Clinical Trials Register on 8 April 2022 (DRKS 00,027,836).

8 October 2026 in Epilepsia
Verified
Journal Article
Open access
PDF file
HTHannah Traben
Hannah Traben
JHJulia Herzig-Nichtweiß
Julia Herzig-Nichtweiß
LLLisa Langenbruch
Lisa Langenbruch
FKFelix Kohle
Felix Kohle
JPJohann Pelz
Johann Pelz
IGIGNITE! Study Group
IGNITE! Study Group
Objectives: Acute symptomatic epileptic seizures (ASySs) occur in temporal proximity to acute brain insults. Given their low risk of subsequent unprovoked seizures, current guidelines recommend either no treatment with anti‐seizure medication (ASM) or early discontinuation, yet ASM treatment is often continued beyond hospital discharge. We aimed at investigating the cumulative 3‐year risk and predictors of unprovoked seizures after ASySs and assessing the effect of ASM treatment duration. Methods: The prospective, multicenter register on the prognosis of acute symptomatic seizures (PROSE register) recruited adults with clinically apparent, acute symptomatic, first‐ever epileptic seizure, excluding status epilepticus. Primary endpoint was occurrence of a first unprovoked seizure. The impact of ASM treatment duration was assessed through a Cox regression correcting for treatment selection bias. The chance of occurrence of a seizure in the next year (COSY) was calculated to evaluate driving eligibility. Results: The 3‐year cumulative incidence of unprovoked seizures was 14% [95% confidence interval (CI): 7%–21%] among 122 participants with structural etiologies. Male sex (hazard ratio [HR] 9.3; 95% CI 1.9–45.1), early epileptiform electroencephalography (EEG) activity (HR 7.4; 95% CI 1.8–31.1), and latency ≥48 h between onset of underlying condition and ASyS (HR 4.8; 95% CI 1.3–18.1) were independently associated with unprovoked seizures. ASM treatment duration had no apparent effect (HR 1; 95% CI 1–1; p = .84). The initial COSY was 10% and fell below 2% within 2 years. Significance: Even in structural etiologies, ASySs bear a relatively low risk of later unprovoked seizures. There is still no evidence favoring prolonged ASM treatments. These findings may help preventing ASM overtreatment and guide counseling on driving eligibility.